VERACYTE, INC. Deferred Income Tax Expense (Benefit)
VERACYTE, INC. (VCYT) reported Deferred Income Tax Expense (Benefit) of -$580.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-26
- VERACYTE, INC. deferred income tax expense (benefit) for the quarter ending 2023-12-31 was -$3.08M.
- VERACYTE, INC. deferred income tax expense (benefit) for the quarter ending 2023-09-30 was -$968.00K.
- VERACYTE, INC. deferred income tax expense (benefit) for the quarter ending 2023-06-30 was $125.00K.
- VERACYTE, INC. deferred income tax expense (benefit) for the quarter ending 2023-03-31 was $0.00.
- VERACYTE, INC. deferred income tax expense (benefit) for fiscal 2025 was -$580.00K.
- VERACYTE, INC. deferred income tax expense (benefit) for fiscal 2024 was -$230.00K.
- VERACYTE, INC. deferred income tax expense (benefit) for fiscal 2023 was -$3.92M.
- VERACYTE, INC. deferred income tax expense (benefit) for fiscal 2022 was -$427.00K.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$580.00K 10-K · filed 2026-02-26 | |||
| 2024-12-31 | -$230.00K 10-K · filed 2026-02-26 | |||
| 2023-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$4.05M derived: sum of 2 quarters · filed 2026-02-26 | -$3.92M derived: sum of 3 quarters · filed 2026-02-26 | -$3.92M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$968.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$843.00K derived: sum of 2 quarters · filed 2023-11-08 | -$843.00K 10-Q · filed 2023-11-08 | -$1.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $125.00K 10-Q · filed 2023-08-09 | -$32.00K derived: sum of 3 quarters · filed 2025-02-28 | -$184.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-05 | -$157.00K derived: sum of 2 quarters · filed 2025-02-28 | -$309.00K derived: sum of 3 quarters · filed 2025-02-28 | -$424.00K derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$309.00K derived: sum of 2 quarters · filed 2025-02-28 | -$424.00K derived: sum of 3 quarters · filed 2025-02-28 | -$427.00K 10-K · filed 2025-02-28 |
| 2022-09-30 | -$152.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$267.00K derived: sum of 2 quarters · filed 2023-11-08 | -$270.00K 10-Q · filed 2023-11-08 | -$1.18M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$115.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$118.00K 10-Q · filed 2023-08-09 | -$1.02M derived: sum of 3 quarters · filed 2024-02-29 | -$2.37M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$3.00K 10-Q · filed 2023-05-05 | -$909.00K derived: sum of 2 quarters · filed 2024-02-29 | -$2.26M derived: sum of 3 quarters · filed 2024-02-29 | -$2.41M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | -$906.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$2.26M derived: sum of 2 quarters · filed 2024-02-29 | -$2.41M derived: sum of 3 quarters · filed 2024-02-29 | -$6.20M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$1.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$1.50M derived: sum of 2 quarters · filed 2022-11-03 | -$5.30M 10-Q · filed 2022-11-03 | -$5.30M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | -$152.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | -$3.95M 10-Q · filed 2022-08-03 | -$3.95M derived: sum of 3 quarters · filed 2023-03-01 | -$3.95M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$3.79M 10-Q · filed 2022-05-04 | -$3.79M derived: sum of 2 quarters · filed 2023-03-01 | -$3.79M derived: sum of 3 quarters · filed 2023-03-01 | -$3.79M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $0.00 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |